Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRT-042 in MDD with Acute Suicidal Ideation or Behavior
NCT07193901Phase 2Completed
- Sponsor
- Sichuan Prite Pharmaceutical
- Start
- May 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PRT-042 in major depressive disorder (MDD), sponsored by Sichuan Prite Pharmaceutical. Started May 2025; status: completed.
02
Drugs
PRT-042
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07193901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07193901.